News | News By Subject | News by Disease News By Date | Search News
Get Our FREE
Industry eNewsletter
email:    
   

Here’s Why Sucampo (SCMP) Paid $200M For Its PhIII Niemann-Pick Drug



8/11/2017 8:38:54 AM

  Life Sciences Jobs  
  • Newest Jobs - Last 24 Hours
  • California Jobs
  • Massachusetts Jobs
  • New Jersey Jobs
  • Maryland Jobs
  • Washington Jobs
  View More Jobs
Investigators have outlined the results of a small, single-arm study of a new drug for Niemann-Pick type C disease which inspired a $200 million biotech buyout earlier this year.

The drug is cyclodextrin, or at least a unique mixture of 2-hydroxypropyl-ß- cyclodextrins (HPßCD) that Vtesse had moved into a pivotal study after gleaning positive data from a study with 14 patients. Sucampo bagged the biotech and its drug for $200 million in April, taking over control of the Phase III.

Read at News Release


comments powered by Disqus
   

ADD TO DEL.ICIO.US    ADD TO DIGG    ADD TO FURL    ADD TO STUMBLEUPON    ADD TO TECHNORATI FAVORITES